(Q38050872)

27 August 2017

title

The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review (English)

1 reference

chronic renal insufficiency

27 August 2017

main subject

1 reference

inferred from title

author name string

Anastasia G Ptinopoulou

series ordinal

1

1 reference

27 August 2017

Maria I Pikilidou

series ordinal

2

1 reference

27 August 2017

Anastasios N Lasaridis

series ordinal

3

1 reference

27 August 2017

publication date

11 October 2012

1 reference

27 August 2017

published in

Hypertension Research

1 reference

27 August 2017

volume

36

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

91-101

1 reference

Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994).

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Changes in renal risk factors versus renal function outcome during follow-up in a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Cellular and molecular mechanisms of proteinuria in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Efficacy and safety of benazepril for advanced chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Acute renal failure in the elderly: particular characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Ca2+ channel subtypes and pharmacology in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective, 'real-world' comparison with amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Differential effects of calcium antagonist subclasses on markers of nephropathy progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Effects of long-acting ACE inhibitor (temocapril) and long-acting Ca channel blocker (amlodipine) on 24-h ambulatory BP in elderly hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Renal afferent denervation prevents hypertension in rats with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

An Overview of the Pharmacodynamic Properties and Therapeutic Potential of Combined α- and β-Adrenoceptor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Antioxidant activity of beta-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Microalbuminuria and oxidative stress in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Role for $beta;-blockers in the management of diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Nephrologists neglect administration of betablockers to dialysed diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Acute myocardial infarction and renal dysfunction: a high-risk combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Should beta-blockers be used to control hypertension in people with chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Should diuretics always be included as initial antihypertensive management in early-stage CKD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Glucose and cholesterol elevations during thiazide therapy: Intention-to-treat versus actual on-therapy experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Effect of aldosterone on renal transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Aldosterone blockade: an emerging strategy for abrogating progressive renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

HFSA 2010 Comprehensive Heart Failure Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

THE PHARMACOLOGY OF CENTRALLY ACTING ANTIHYPERTENSIVE DRUGS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Aliskiren: the first direct renin inhibitor for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Endothelin receptors in normal and diseased kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Endothelin antagonists and resistant hypertension in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Prevention of microalbuminuria in patients with type 2 diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Blood pressure and end-stage renal disease in men

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Thiazide diuretic monotherapy for hypertension: diuretic's dark side just got darker

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Plasma aldosterone concentrations in chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

ETB-mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.157

7 January 2021

Identifiers

DOI

10.1038/HR.2012.157

1 reference

27 August 2017

1 reference